mab in adults with CPUO, to support progression to late-stage development.8








“We’re excited to launch this study exploring nemolizumab’s potential in patients with CPUO, many of whom have struggled for years without effective treatment options. Nemolizumab has shown outstanding efficacy in prurigo nodularis – a condition that shares important clinical and mechanistic features with CPUO – through its targeted inhibition of IL-31 signaling. With recent research further reinforcing IL-31 as a key driver of itch in CPUO, we’re hopeful that nemolizumab could offer meaningful relief to patients with this condition.”

DOCTOR SHAWN KWATRA, M.D.

LEAD INVESTIGATOR, CHRONIC PRURITUS OF UNKNOWN ORIGIN PHASE II STUDY










New data provides a better understanding of the ke
=*=*=*=*=*=
当前为第3/10页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页